WeVote
Log In

Bill

Bill

A 4054

Requires certain businesses in which alcohol or cannabis is consumed have opioid antagonists

2025 Regular Session Introduced by Keith Brown and 2 co-sponsors

Requires certain venues that serve alcohol or cannabis to stock opioid antagonists (naloxone) on site to improve overdose response and save lives.

REFERRED TO ECONOMIC DEVELOPMENT
0
WeVote Research Nonpartisan
Bill Summary · A 4054

Summary of Bill A 4054

Quick Overview

  • Bill Number: A 4054
  • Title: Requires certain businesses in which alcohol or cannabis is consumed have opioid antagonists
  • Primary Sponsor: Keith Brown
  • Cosponsors: Joe DeStefano, David McDonough
  • Introduced: January 31, 2025
  • Status: Referred to the Economic Development committee
  • Related bills (prior-session): A 10369, A 5580

What the bill would do

The bill aims to mandate the presence of opioid antagonists at certain businesses where alcohol or cannabis is consumed. An opioid antagonist is a medication (commonly referred to as naloxone in practice) used to counteract the effects of an opioid overdose. The stated objective is to improve overdose response capacity in venues where intoxicants are served or consumed.

Scope and who would be affected

  • The requirement applies to “certain businesses” in which alcohol or cannabis is consumed. The exact types of establishments covered (e.g., bars, lounges, cannabis consumption sites, events, or other venues) are not specified in the information provided.
  • Businesses would presumably be responsible for having the antagonists accessible and possibly for related training or maintenance, depending on the full text of the measure (not included in the summary you provided).

Key provisions (based on the bill’s stated purpose)

  • Mandate: On-site availability of opioid antagonists at qualifying establishments.
  • Operational expectations: The summary does not include details on quantities, placement, training requirements, expiration-date management, or who may administer the antagonist.
  • Enforcement and penalties: Not specified in the provided information.

Note: The full bill text would clarify the exact compliance requirements, exemptions, training obligations, record-keeping, and enforcement mechanisms.

Legislative status and actions

  • The bill was introduced on January 31, 2025, and referred to the Economic Development committee.
  • The legislative actions listed show the same committee referral on January 31, 2025, with a duplicate entry, indicating a clerical repetition rather than a separate action.

Related context

  • Related bills from prior sessions (A 10369 and A 5580) suggest ongoing legislative interest in overdose prevention or on-site availability of opioid antagonists. The current bill may build on or mirror concepts explored in those prior measures.

Potential impact and considerations

  • Public health: Increased access to opioid antagonists could improve response times to overdoses in nightlife and hospitality settings.
  • Economic/operational: Businesses would incur costs for stocking the antagonists, potential training, and ongoing maintenance; compliance timelines are not specified here.
  • Implementation questions: Exact coverage, required number of units, whether staff must be trained, permissible administration, and who bears responsibility for replacement and disposal.

Next steps for readers

  • Monitor updates from the Economic Development committee for the full text, defined scope, implementation timeline, exemptions, and enforcement details.
  • If you represent a covered business, seek the official bill language and any fiscal notes or regulatory impact statements once released to understand costs and compliance steps.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.